Control of pertussis-Lessons learnt from a 10-year surveillance programme in Sweden

Vaccine

Volumn 27, Issue 42, 2009, Pages 5709-5718

  Carlsson, Rose Marie ^a   Trollfors, Birger ^b  

^a Swedish Armed Forces   (Sweden)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

Acellular pertussis vaccine; Bordetella pertussis; Surveillance

Indexed keywords

PERTUSSIS VACCINE;

BORDETELLA PERTUSSIS; CONFERENCE PAPER; DISEASE CLASSIFICATION; DISEASE TRANSMISSION; DRUG EFFICACY; HEALTH PROGRAM; HEALTH SURVEY; HERD; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; IMMUNITY; INCIDENCE; LABORATORY TEST; MATHEMATICAL MODEL; MORBIDITY; MORTALITY; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; SEROLOGY; SWEDEN; VACCINATION; WORLD HEALTH ORGANIZATION;

CHILD; DISEASE NOTIFICATION; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION PROGRAMS; PERTUSSIS VACCINE; POPULATION SURVEILLANCE; SWEDEN; WHOOPING COUGH;

EID: 69949108382     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.092     Document Type: Conference Paper

References (35)

1. Miller E. Potential and existing impact of vaccines on disease epidemiology. In: Bloom B.R., and Lambert P.H. (Eds). The vaccine book (2003), Elsevier Science, San Diego 37-50
2. Carlsson RM, Gustafsson L. Ten year report: pertussis surveillance in Sweden. Progress report October 1, 1997-December 31, 2007 with an executive summary. Available from URL: http://www.smittskyddsinstitutet.se/upload/SMI-rapport%20nr%204-2008.pdf [accessed 4 February 2009]. Ten year report, Appendix 1 (Person-time calculations). Available from URL: http://www.smittskyddsinstitutet.se/upload/10-y%20report-app%201.pdf [accessed 4 February 2009]. Ten year report, Appendix 2 (Person-time of follow-up and incidence calculations for GSK vaccine specific cohorts). Available from URL: http://www.smittskyddsinstitutet.se/upload/10-y%20report-app%202%20-%20G SK.pdf [accessed 4 February 2009]. Ten year report, Appendix 2 (Person-time of follow-up and incidence calculations for Sanofi Pasteur vaccine specific cohorts). Available from URL: http://www.smittskyddsinstitutet.se/upload/10-y%20report-app%202-%20SP%2 0MSD.pdf [accessed 4 February 2009]; 2008.
3. Carlsson RM, Gustafsson L. Ten year report: pertussis in Göteborg study area. Technical report October 1, 1997 until December 31, 2007, including enhanced surveillance January 1, 2003 until December 31, 2007, with an executive summary. Available from URL: http://www.smittskyddsinstitutet.se/upload/SMI-rapport%20nr%205-2008.pdf [accessed 4 February 2009]; 2008.
4. Mooi F.R., van Oirschot H., Heuvelman K., van der Heide H.G., Gaastra W., and Willems R.J. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 66 (1998) 670-675
5. Taranger J., Trollfors B., Bergfors E., Knutsson N., Sundh V., Lagergård T., et al. Mass vaccination of children with pertussis toxoid-decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 33 (2001) 1004-1010
6. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., and Heijbel H. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350 (1997) 1569-1577
7. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., and Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334 (1996) 349-355
8. Cherry J.D. Epidemiology of pertussis. Pediatr Infect Dis J 25 (2006) 361-362
9. Celentano L.P., Massari M., Paramatti D., Salmaso S., Tozzi A.E., and EUVAC-NET Group. Resurgence of pertussis in Europe. Pediatr Infect Dis J 24 (2005) 761-765
10. World Health Organisation. WHO meeting on case definition of pertussis. Geneva, 10-11 January 1991. Geneva: WHO, MIN/EPI/PET/91, vol. 1. p. 4-5.
11. Commission of the European Communities. 2008/426/EC: Commission Decision of 28 April 2008 amending Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the Community network under Decision No 2119/98/EC of the European Parliament and of the Council. Available from URL: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2008:159:0046 :01:EN:HTML [accessed 24 February 2009].
12. Bonacruz-Kazzi G., McIntyre P., Hanlon M., and Menzies R. Diagnostic testing and discharge coding for whooping cough in a children's hospital. J Paediatr Child Health 39 (2003) 586-590
13. Crowcroft N.S., Andrews N., Rooney C., Brisson M., and Miller E. Deaths from pertussis are underestimated in England. Arch Dis Child 86 (2002) 336-338
14. Crowcroft N.S., Booy R., Harrison T., Spicer L., Britto J., Mok Q., et al. Severe and unrecognised: pertussis in UK infants. Arch Dis Child 88 (2003) 802-806
15. Bonmarin I, Lévy-Bruhl D, Baron S, Guiso N, Njamkepo E, Caro V, et al. Pertussis surveillance in French hospitals: results from a 10 year period. Euro Surveill 2007;12(1) [Epub ahead of print]. Available online: http://www.eurosurveillance.org/em/v12n01/1201-226.asp.
16. RENACOQ. Available from URL: http://www.invs.sante.fr/surveillance/coqueluche/donnees_96_04.pdf [accessed 4 February 2009].
17. Hviid A., Stellfeld M., Andersen P.H., Wohlfahrt J., and Melbye M. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark. Vaccine 22 (2004) 3530-3534
18. Van Buynder P.G., Owen D., Vurdien J.E., Andrews N.J., Matthews R.C., and Miller E. Bordetella pertussis surveillance in England and Wales: 1995-7. Epidemiol Infect 123 (1999) 403-411
19. Cherry J.D., Gornbein J., Heininger U., and Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16 (1998) 1901-1906
20. Storsaeter J., Hallander H.O., Gustafsson L., and Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16 (1998) 1907-1916
21. Taranger J., Trollfors B., Lagergård T., Sundh V., Bryla D.A., Schneerson R., et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 181 (2000) 1010-1013
22. Hallander H.O., Gustafsson L., Ljungman M., and Storsaeter J. Pertussis antitoxin decay after vaccination with DTPa. Response to a first booster dose 31/2-61/2 years after the third vaccine dose. Vaccine 23 (2005) 5359-5364
23. Gustafsson L., Hessel L., Storsaeter J., and Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 118 (2006) 978-984
24. White J.M., Fairley C.K., Owen D., Matthews R.C., and Miller E. The effect of an accelerated immunisation schedule on pertussis in England and Wales. Commun Dis Rep CDR Rev 6 (1996) R86-R91
25. Skowronski D.M., De Serres G., MacDonald D., Wu W., Shaw C., Macnabb J., et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis 185 (2002) 1448-1453
26. Kandola K., Lea A., White W., and Santos M. A comparison of pertussis rates in the Northwest Territories: pre- and postacellular pertussis vaccine introduction in children and adolescents. Can J Infect Dis Med Microbiol 16 (2005) 271-274
27. Trollfors B., Taranger J., Lagergård T., Sundh V., Bryla D.A., Schneerson R., et al. Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr Infect Dis J 17 (1998) 196-199
28. Schwenkenbecher A. Keuchhusten bei Erwachsenen. Med Klin 17 (1921) 1447-1448
29. Mannerstedt G. Pertussis in adults. J Pediatr 34 (1934) 596-600
30. Bisgard K.M., Pascual F.B., Ehresmann K.R., Miller C.A., Cianfrini C., Jennings C.E., et al. Infant pertussis: who was the source?. Pediatr Infect Dis J 23 (2004) 985-989
31. Wendelboe A.M., Njamkepo E., Bourillon A., Floret D.D., Gaudelus J., Gerber M., et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 26 (2007) 293-299
32. Baron S., Njamkepo E., Grimprel E., Begue P., Desenclos J.C., Drucker J., et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 17 (1998) 412-418
33. Halperin S.A., Wang E.E., Law B., Mills E., Morris R., Déry P., et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991-1997: report of the Immunization Monitoring Program-Active (IMPACT). Clin Infect Dis 28 (1999) 1238-1243
34. Granström M., Olinder-Nielsen A.M., Holmblad P., Mark A., and Hanngren K. Specific immunoglobulin for treatment of whooping cough. Lancet 338 (1991) 1230-1233
35. Hallander H.O., Advani A., Donnelly D., Gustafsson L., and Carlsson R.M. Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol 43 (2005) 2856-2865